Skip to main navigation
CareDx
  • COMPANY
    • Management Team
    • Board of Directors
    • Compliance
    • Careers
      • Current Openings
      • Benefits
  • PRODUCTS
    • HeartCare, AlloMap
    • KidneyCare, AlloSure
    • Laboratory Products
    • Ottr
  • INVESTORS
  • CONTACT US

Press Releases

Media Inquiries - media@caredx.com

Date Title and Summary Additional Formats
Toggle Summary May 24, 2022 CareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell Transplantation
CareDx Expands Transplant Portfolio in Europe SOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) --  CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for
View HTML
Toggle Summary May 18, 2022 CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung Allograft Dysfunction
Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant Outcomes SOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically
View HTML
Toggle Summary May 17, 2022 In CareDx-Initiated IP Litigation Against Natera, Natera Now Drops 1 of 2 Patents Originally Asserted Against CareDx
Natera Recycles Old IP for New Lawsuits SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant
View HTML
Toggle Summary May 11, 2022 CareDx Showcases Latest Innovation in Transplantation at European EFI 2022 Conference
Posters and Symposium Feature Latest Advances in AlloSeq Portfolio Including HLA Typing and Hematopoietic Stem Cell and Organ Transplant Monitoring SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery,
View HTML
Toggle Summary May 05, 2022 CareDx Reports First Quarter 2022 Results
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today reported
View HTML
Toggle Summary May 05, 2022 CareDx Validates Clinical Performance of AlloMap Kidney to Comprehensively Assess Transplant Rejection
OKRA Multi-Center Prospective Study Confirms AlloMap Kidney Detects ABMR and TCMR Allograft Rejection SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically
View HTML
Toggle Summary Apr 28, 2022 CareDx Congratulates Board Member Dr. Hannah Valantine on ISHLT Lifetime Achievement Award
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced
View HTML
Toggle Summary Apr 28, 2022 CareDx Extends Artificial Intelligence Leadership to Heart Transplantation
New Addition to CareDx HeartCare Multimodality Portfolio Can Enable More Precise, Personalized Patient Care SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of
View HTML
Toggle Summary Apr 27, 2022 CareDx to Report First Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – today announced it will report
View HTML
Toggle Summary Apr 27, 2022 International Society for Heart and Lung Transplantation Foundation Selects Reg Seeto as Corporate Chair
CareDx CEO and President, Reg Seeto, Joins ISHLT Foundation Global Steering Committee Focused on Driving Innovations for Heart and Lung Transplant Patients SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery,
View HTML

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • …
  • Next page Next
  • Last page Last
Displaying 1 - 10 of 383 results

Investor Relations

  • Investor Relations
  • Press Releases
  • Events & Presentations
  • Corporate Governance
  • Financials & Filings
  • Stock Information
  • Analyst Coverage
  • Investor FAQs
  • Contact Us

Shareholder Tools

Printed Materials
E-mail Alerts
Downloads
RSS
Print
Share
  • Facebook
  • LinkedIn
  • Twitter
  • RSS

    ©2004-2022 CareDx, Inc. All Rights Reserved.    CareDx is a registered trademark of CareDx, Inc.

    Privacy & Compliance